Compugen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.01.24	Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial (RTTNews)
19.12.23	Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program (RTTNews)
02.10.23	Compugen Gets Patent In Japan For Combination Of Anti-PVRIG, TIGIT, PD-1 Antibody To Treat Cancer (RTTNews)
06.12.22	Compugen: COM701 In Dual And Triple Combination Shows Preliminary Durable Anti-Tumor Activity (RTTNews)
01.12.22	Compugen: COM701 Combinations Show 20% Overall Response Rate, 40% Disease Control Rate (RTTNews)
16.11.22	Compugen Reports Advancement Of AZD2936 Into Phase 2 By AstraZeneca; Triggers Milestone Payment (RTTNews)
12.09.22	Compugen Names Alberto Sessa CFO, Effective Nov. 1 (RTTNews)
20.05.22	Pre-market Movers: ROST, EVEX, TIGO, CGEN, PANW… (RTTNews)
09.03.22	Compugen: New Data Shows Potential Of Combining TIGIT, PVRIG In Treatment Of Multiple Myeloma (RTTNews)
09.12.21	Why Compugen Is Rising In Pre-market? (RTTNews)
19.08.21	Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development (PR Newswire)
28.07.21	Compugen Reports Second Quarter 2021 Results (PR Newswire)
19.07.21	Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207 (PR Newswire)
15.07.21	Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies (PR Newswire)
14.07.21	Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021 (PR Newswire)
30.06.21	Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study (PR Newswire)
29.06.21	Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis (PR Newswire)
08.06.21	Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting (PR Newswire)
13.05.21	Stock Alert: Compugen Up 10% As Loss Narrower Than Street View (RTTNews)
23.12.20	Compugen To Receive $2 Mln Milestone Payment From AstraZeneca Under License Deal - Quick Facts (RTTNews)
23.12.20	Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products (PR Newswire)
12.06.20	Stock Alert: Compugen Jumps 9% (RTTNews)
05.06.20	CYCN Awaits Sickle Cell Disease Data, TTPH Finalizes Its Suitor, ADMS Faces FDA In Feb (RTTNews)
01.06.20	Compugen: FDA Allows Phase 1/2 Study Evaluating COM701 With BMS-986207 And Nivolumab (RTTNews)
06.05.20	Compugen Reports First Quarter 2020 Results (PR Newswire)
16.04.20	RCUS Abuzz, FDA Approves First Therapy For LG UTUC, VNDA Joins COVID-19 Battle (RTTNews)
20.02.20	Compugen Reports Fourth Quarter and Full Year 2019 Results (PR Newswire)
03.02.20	Compugen (CGEN) Hits A High - A Transformative Year Gone, A Busy Year Ahead (RTTNews)
11.11.19	Compugen Reports Third Quarter 2019 Results (PR Newswire)
01.11.19	Healthcare Stocks That Hit New Highs ( REPH, CNMD, DRNA,...) (RTTNews)
05.08.19	Compugen Reports Second Quarter 2019 Results (PR Newswire)
22.07.19	Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET (PR Newswire)
03.04.19	Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting (PR Newswire)
05.03.19	Compugen to Present at the Cowen and Company 39th Annual Health Care Conference (PR Newswire)
14.02.19	Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET (PR Newswire)
23.01.19	7 Top Gainers In Healthcare Sector (MDWD, RFL, CGEN...) (RTTNews)
11.10.18	Bristol-Myers, Compugen To Jointly Evaluate Combination Of COM701 With Opdivo (RTTNews)
05.09.18	Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors (PR Newswire)
01.08.18	Compugen Reports Second Quarter 2018 Results (PR Newswire)
02.07.18	Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody (PR Newswire)
11.06.18	Compugen Announces the Appointment of New Board Members (PR Newswire)
09.05.18	Compugen Reports First Quarter 2018 Results (PR Newswire)
27.04.18	Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody (PR Newswire)
17.04.18	Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy (PR Newswire)
26.03.18	Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer (PR Newswire)
27.02.18	ZSAN Explodes, TTPH On Radar, APLS Catches Eyes, CERC Hits A High (RTTNews)
21.02.18	Compugen Reports Fourth Quarter and Full Year 2017 Results (PR Newswire)
08.02.18	Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET (PR Newswire)
06.02.18	Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology (PR Newswire)
19.01.18	BGNE Up, Up And Away, Data Vindicates CGEN's Strategy, JNCE Awaits ICONIC Data (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	536.60	1.05 %	K V
Sonova Hldg	307.00	0.79 %	K V
Roche Hldg G	252.50	0.44 %	K V
Nestle	76.16	0.42 %	K V
Novartis	92.13	0.22 %	K V
Swiss Re	127.95	-0.66 %	K V
ABB	49.14	-0.81 %	K V
Sika	226.60	-0.87 %	K V
CieFinRichemont	121.25	-0.90 %	K V
Logitech Intl	70.52	-2.03 %	K V

mehr

26.11.24		Gute Stimmung in New York: Börsianer lassen NASDAQ Composite schlussendlich steigen
22.11.24		Starker Wochentag in New York: NASDAQ Composite am Nachmittag auf grünem Terrain
12.11.24		Schwacher Handel: NASDAQ Composite zeigt sich zum Ende des Dienstagshandels schwächer
04.11.24		Verluste in New York: NASDAQ Composite beginnt Montagshandel mit Verlusten
03.10.24		Verluste in New York: NASDAQ Composite fällt zum Handelsende zurück
27.09.24		Zurückhaltung in New York: NASDAQ Composite liegt am Nachmittag im Minus
27.09.24		Freundlicher Handel in New York: NASDAQ Composite verbucht zum Handelsstart Zuschläge
09.09.24		Aufschläge in New York: Zum Handelsende Gewinne im NASDAQ Composite

26.11.24

Gute Stimmung in New York: Börsianer lassen NASDAQ Composite schlussendlich steigen

22.11.24

Starker Wochentag in New York: NASDAQ Composite am Nachmittag auf grünem Terrain

12.11.24

Schwacher Handel: NASDAQ Composite zeigt sich zum Ende des Dienstagshandels schwächer

04.11.24

Verluste in New York: NASDAQ Composite beginnt Montagshandel mit Verlusten

03.10.24

Verluste in New York: NASDAQ Composite fällt zum Handelsende zurück

27.09.24

Zurückhaltung in New York: NASDAQ Composite liegt am Nachmittag im Minus